Cancer Tumor Profiling Market Forecast, Trends, Opportunities And Growth Drivers 2025-2034

For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.

How has the cancer tumor profiling grown historically, and what trends indicate future expansion?

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (ai) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

Which key factors are driving the expansion of the cancer tumor profiling industry?
The increasing incidences of cancer across the globe are expected to propel the growth of the cancer and tumor profiling market going forward. Cancer is a disease in which some cells in the body get uncontrollably large and spread to other parts of the body. As the number of cancer cases rises, so does the demand for cancer tumor profiling, which enables doctors to determine the severity of the disease. For instance, in 2024, the American Cancer Society, a US-based professional organization based, reported that 2 million new cancer cases were diagnosed in the country, up from 1.9 million new cases in 2023. Therefore, the increasing incidences of cancer across the globe drive the growth of the cancer and tumor profiling market.

How is the cancer tumor profiling market segmented by product, application, and end-user?
The cancer tumor profiling market covered in this report is segmented –

1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies
3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types
4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer, Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

How are emerging trends transforming the cancer tumor profiling market dynamics?
The increasing research and development activities have emerged as the key trend gaining popularity in cancer and tumor profiling market. Major companies operating in cancer and tumor profiling sector are focused on research and development activities to meet consumer demand and reinforce their position. For instance, QIAGEN N.V, a German company that develops sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe as a tool to help identify breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic assay for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and first to allow testing of both DNA from plasma specimens or FFPE tissue.

Which leading companies are dominating the cancer tumor profiling market landscape?
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

Which geographic areas are expected to offer the highest growth opportunities in thecancer tumor profiling market?
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Can Companies Use The Cancer Tumor Profiling Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.

Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

Need Customized Data On Cancer Tumor Profiling Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.

Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company